For a long time,the contradiction between the high incidence and the low control rate of hypertension has been a global problem.Many patients failto achieve or maintain the target blood-pressure that guideline recommended.To make up for the shortcomings of the traditional antihypertensive route,renal denervation has been widely studied in recent years as anew way to control blood pressure,in which catheter-directed techniques are used to ablate portions of the renal artery to reduce sympathetic activity.In the process of development of this technology,there are also twists and turns.At present,it has developed into three main procedures,including radiofrequency ablation,ultrasound ablation and ethanol ablation.It has increasingly been shown to be a safe and well-tolerated intravascular intervention that reliably lowers blood pressure and ultimately improves cardiovascular outcomes.At the same time,renal denervation may also play an important role in tachyarrhythmia and heart failure.This review aims to discuss the possible principles of this strategy,summarizethe classification and clinical evidence of this procedure,emphasize the advantages in lowering blood pressure throughout 24 hours and reducing themedication burden,point out the people that may benefit more from the procedure and highlight the possible directions for its future application.